[go: up one dir, main page]

SG11201906666QA - Methods of preparing cytotoxic benzodiazepine derivatives - Google Patents

Methods of preparing cytotoxic benzodiazepine derivatives

Info

Publication number
SG11201906666QA
SG11201906666QA SG11201906666QA SG11201906666QA SG11201906666QA SG 11201906666Q A SG11201906666Q A SG 11201906666QA SG 11201906666Q A SG11201906666Q A SG 11201906666QA SG 11201906666Q A SG11201906666Q A SG 11201906666QA SG 11201906666Q A SG11201906666Q A SG 11201906666QA
Authority
SG
Singapore
Prior art keywords
international
english
applicant
pct
rule
Prior art date
Application number
SG11201906666QA
Other languages
English (en)
Inventor
Baudouin Gérard
Richard Silva
Michael Miller
Manami Shizuka
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of SG11201906666QA publication Critical patent/SG11201906666QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/16Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06Preparation of nitro compounds
    • C07C201/12Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/19Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04Dimeric indole alkaloids, e.g. vincaleucoblastine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
SG11201906666QA 2017-01-25 2018-01-24 Methods of preparing cytotoxic benzodiazepine derivatives SG11201906666QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762450270P 2017-01-25 2017-01-25
PCT/US2018/014956 WO2018140435A1 (en) 2017-01-25 2018-01-24 Methods of preparing cytotoxic benzodiazepine derivatives

Publications (1)

Publication Number Publication Date
SG11201906666QA true SG11201906666QA (en) 2019-08-27

Family

ID=61189535

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906666QA SG11201906666QA (en) 2017-01-25 2018-01-24 Methods of preparing cytotoxic benzodiazepine derivatives

Country Status (23)

Country Link
US (4) US10385071B2 (pl)
EP (2) EP3573948B1 (pl)
JP (3) JP7066725B2 (pl)
KR (2) KR20230005410A (pl)
CN (3) CN116102615A (pl)
AU (3) AU2018213202B2 (pl)
CA (1) CA3050262A1 (pl)
DK (1) DK3573948T3 (pl)
ES (1) ES2935346T3 (pl)
FI (1) FI3573948T3 (pl)
HR (1) HRP20230002T1 (pl)
HU (1) HUE060746T2 (pl)
IL (3) IL293645A (pl)
LT (1) LT3573948T (pl)
PL (1) PL3573948T3 (pl)
PT (1) PT3573948T (pl)
RS (1) RS63871B1 (pl)
RU (2) RU2021138005A (pl)
SG (1) SG11201906666QA (pl)
SI (1) SI3573948T1 (pl)
SM (1) SMT202300001T1 (pl)
TW (3) TW202400551A (pl)
WO (1) WO2018140435A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230002T1 (hr) 2017-01-25 2023-02-17 Immunogen, Inc. Postupci pripreme citotoksičnih derivata benzodiazepina
CA3119358A1 (en) 2018-11-12 2020-05-22 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
IL283047B2 (en) 2018-11-12 2024-04-01 Immunogen Inc Methods for preparing cytotoxic benzodiazepine derivatives
TW202102506A (zh) * 2019-03-29 2021-01-16 美商伊繆諾金公司 苯二氮平衍生物
CN119486758A (zh) 2022-06-30 2025-02-18 东丽株式会社 癌的治疗和/或预防用药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9018601D0 (en) 1990-08-24 1990-10-10 Fujisawa Pharmaceutical Co Tricyclic compounds
AP4012A (en) 2010-12-21 2017-01-22 Janssen Pharmaceutica Nv NOVEL ANTIFUNGAL 5,6-DIHYDRO-4H-PYRROLO[1,2-a][1,4]- BENZODIAZEPINES AND 6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINES SUBSTITUTED WITH BICYCLIC BENZENE DERIVATIVES
SMT201900181T1 (it) * 2011-02-15 2019-05-10 Immunogen Inc Metodi di preparazione di coniugati
MX2017009145A (es) * 2015-01-14 2017-11-22 Bristol Myers Squibb Co Dimeros de benzodiazepina, conjugados de estos, y sus metodos de preparacion y uso.
KR20240063203A (ko) * 2015-06-29 2024-05-09 이뮤노젠 아이엔씨 항-cd123 항체 및 이들의 접합체와 유도체
EP3325483B1 (en) * 2015-07-21 2019-10-02 ImmunoGen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
HRP20230002T1 (hr) 2017-01-25 2023-02-17 Immunogen, Inc. Postupci pripreme citotoksičnih derivata benzodiazepina

Also Published As

Publication number Publication date
KR20230005410A (ko) 2023-01-09
AU2018213202B2 (en) 2022-03-24
CN116554262A (zh) 2023-08-08
TWI805325B (zh) 2023-06-11
CA3050262A1 (en) 2018-08-02
KR102480594B1 (ko) 2022-12-26
US20180251474A1 (en) 2018-09-06
IL293645A (en) 2022-08-01
US10844078B2 (en) 2020-11-24
IL268213B (en) 2021-12-01
TW201831495A (zh) 2018-09-01
PT3573948T (pt) 2023-01-11
RS63871B1 (sr) 2023-02-28
JP7066725B2 (ja) 2022-05-13
JP2020505404A (ja) 2020-02-20
IL268213A (en) 2019-09-26
PL3573948T3 (pl) 2023-01-30
CN110225904A (zh) 2019-09-10
TWI763771B (zh) 2022-05-11
US20230039161A1 (en) 2023-02-09
RU2762891C2 (ru) 2021-12-23
US11981687B2 (en) 2024-05-14
RU2019125133A3 (pl) 2021-05-27
US20210139510A1 (en) 2021-05-13
FI3573948T3 (fi) 2023-01-13
KR20190116331A (ko) 2019-10-14
WO2018140435A9 (en) 2018-12-27
EP4148044A1 (en) 2023-03-15
EP3573948A1 (en) 2019-12-04
HUE060746T2 (hu) 2023-04-28
TW202229226A (zh) 2022-08-01
DK3573948T3 (da) 2023-01-09
US11390633B2 (en) 2022-07-19
AU2018213202A1 (en) 2019-08-22
WO2018140435A1 (en) 2018-08-02
TW202400551A (zh) 2024-01-01
AU2022201572B2 (en) 2024-03-14
IL287405A (en) 2021-12-01
AU2024201119A1 (en) 2024-03-14
SMT202300001T1 (it) 2023-03-17
HRP20230002T1 (hr) 2023-02-17
ES2935346T3 (es) 2023-03-06
US10385071B2 (en) 2019-08-20
US20200002360A1 (en) 2020-01-02
JP2022105096A (ja) 2022-07-12
IL287405B (en) 2022-07-01
JP7400005B2 (ja) 2023-12-18
RU2021138005A (ru) 2022-01-18
EP3573948B1 (en) 2022-10-05
CN116102615A (zh) 2023-05-12
CN110225904B (zh) 2023-10-27
LT3573948T (lt) 2023-02-10
SI3573948T1 (sl) 2023-03-31
JP2024028860A (ja) 2024-03-05
AU2022201572A1 (en) 2022-03-31
RU2019125133A (ru) 2021-02-26

Similar Documents

Publication Publication Date Title
SG11201907451XA (en) Substituted imidazo-quinolines as nlrp3 modulators
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201811432WA (en) Rna for cancer therapy
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201809082WA (en) Nlrp3 modulators
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201809751XA (en) Egfr inhibitor compounds
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201906666QA (en) Methods of preparing cytotoxic benzodiazepine derivatives
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201907693VA (en) Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201810940XA (en) Methods of treating pancreatic cancer